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Dear Editor,
We would like to thank Dr. Giussani and Dr. Di Cristofori
and their colleagues at the Gerardo Hospital (Monza, Italy) for
their interest in our paper, and we would like to clarify in this
answer certain aspects of our paper as well as elaborate on our
thoughts regarding the use of awake craniotomy (AC) in glio-
blastoma (GBM) surgery.
In their letter to the editor, Dr. Giussani and Dr. Di
Cristofori note potential concerns with the methodology and
inclusion criteria of the studies in our meta-analysis. We agree
that the absence of data on molecular markers such as MGMT
status or IDH wt/mt status (the authors also mentioned the
1p19q codeletion which in our opinion is in this GBM popu-
lation is of less interest) is a limitation of our study. Even
though we acknowledge the importance of molecular markers
in the analysis of GBM (sub)groups, we unfortunately were
not able to include this in our analysis and paper because this
information was not consistently mentioned in the specific
literature we found for this systematic review.
We agree with Dr. Giussani and Dr. Di Cristofori that the
time span of the included studies is quite wide. We did this on
purpose to present an overview of the overall evidence regard-
ing the use of intraoperative stimulation mapping (ISM) in
GBM surgery to its full extent. However, we included only a
few papers from the pre-Stupp era (which we define as papers
published in 2005 or earlier), which—as stated by the earlier
mentioned authors—could have been a bias in the overall
survival analysis. Looking at the data published in our Data
Supplement, we can draw the conclusion that we have includ-
ed 8 studies from the pre-Stupp era. Of those studies, only 3 of
them contain overall survival data. The average median sur-
vival of these 3 papers combined is 13.6 months (weighted).
Two of these papers included patients operated under general
anesthesia (GA) without ISM, with an average median surviv-
al of 13.5 months (weighted), and one paper included patients
operated with the use of ISM, with an average median survival
of 16.4 months. When we compare the average median sur-
vival data of the papers from the pre-Stupp era with the overall
average, we can conclude that this is in line with these survival
data and would be unlikely to represent any bias (GA/without
ISM 13.5 months pre-Stupp vs. 12.0 months overall; with
ISM 16.4 months pre-Stupp vs. 16.9 months overall).
Furthermore, they state that the age of patients is higher in
the group treated under GAwithout ISM in comparison with
the group treated with ISM and that this might represent a bias
in OS analysis. We agree that age is a strong prognostic factor
for e.g. overall survival in GBM patients. Therefore, we fur-
ther analyzed the data regarding the mean age versus overall
survival in our included studies. The average age in the group
treated under GAwithout ISM is 62.4 years (37 studies with
data regarding mean age) as compared with 56.9 years in the
group treated with ISM (9 studies with data regarding mean
age). However, this takes into regard all studies, with and
without relevant overall survival data. When we analyze the
cohort of studies that contain both mean age and overall sur-
vival data (both of these parameters we need to draw conclu-
sions regarding differences between groups), we conclude that
the mean age in the cohort of studies including patients treated
with ISM (3 studies) is actually higher than in the cohort of
studies including patients treated under GAwithout ISM (15
studies) (avg. age 61.2 years in the ISM group as opposed to
60.5 years in the ISM group), which is in contrast with the
statement at the beginning of this paragraph and we therefore
respectfully disprove it.
Dr. Giussani andDr. Di Cristofori inquired us to elaborate on
some aspects regarding the (added) value and use of AC in
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GBM surgery. First, they question if there are real benefits for
GBM patients to have surgery with AC. We feel fortunate to
say that we can state that there are many benefits in using AC in
GBM surgery. In addition to our meta-analysis, we conducted a
retrospective matched case-control study in our center in which
we matched every patient operated under AC with 3 patients
operated under GA (without ISM), including 148 patients in
total [1]. We concluded that the extent of resection was signif-
icantly higher in the AC group: mean extent of resection in the
AC group was 94.89% (SD= 10.57) as compared with 70.30%
in the GA group (SD = 28.37) (p = 0.0001). Furthermore, the
mean rate of late minor postoperative complication in the AC
group (0.03; SD = − 0.16) was significantly lower than in the
GA group (0.15; SD = 0.39) (p = 0.05), which is in line with our
meta-analysis, in which we found that patients operated with
ISM experienced less late neurological complications (mean
rate 0.13 (95% CI 0.20–0.23) vs. 0.21 (95% CI 0.10–0.16);
p < 0.001). Multiple studies show that the extent of resection
improves survival in GBM patients and that patients with gross
total resections (GTR) derived the most benefit from the adju-
vant therapy [2–5]. However, since > 50%of GBMs are located
in or near eloquent areas [6], there is an increased risk of neu-
rological morbidity when increasing extent of resection. This is
in contrast with the fact that due to the limited prognosis of
these patients, preservation of quality of life in these patients
should be the first concern. AC is able to increase extent of
resection in GBM surgery while preserving quality of life,
thereby significantly improving patient outcomes. AC could
thus be of high value in the surgical treatment of GBM in
eloquent areas [7–11].
Secondly, the letter’s authors inquired if subcortical map-
ping is the only way to preserve subcortical white matter tracts
during surgery, given the growth pattern of GBMs. Besides
from brain mapping (during awake craniotomy) are “asleep”
mapping methods another excellent tool to preserve these
tracts (MEP, SSEP, continuous dynamic mapping). For exam-
ple, Prof. Raabe’s Neurosurgery Dept. in Bern (Switzerland)
uses continuous dynamic mapping with a monopolar for
GBM surgeries adjacent to motor eloquent areas [12, 13].
They realize continuous (temporal coverage) and dynamic
(spatial coverage) mapping by integrating the mapping probe
at the tip of the suction device. Acoustic feedback indicates
proximity to the corticospinal tract. New intraoperative devel-
opments like these can be combined with ever-improving di-
agnostics and radiomics (DTI, HARDI, q-ball imaging) to
yield optimal results in GBM surgeries in eloquent areas.
Lastly, they pose the question if an accurate microsurgical
technique, aimed to circumferentially “peal,” can resect the
tumor mass en bloc (when possible) instead of internally as-
pirating it, thereby overpassing the need for AC/ISM in GBM
surgery. We would like to stress that GBMs can never be
resected radically nor circumferentially “pealed” (like, for ex-
ample, in meningioma surgery) because ample evidence has
shown that GBMs are characterized by leaving behind micro-
scopic tumor satellites into the normal brain parenchyma,
deeming tumor recurrences (despite maximal surgical resec-
tion followed by adjuvant chemoradiation) unfortunately in-
evitable [6, 14]. Hence, the very essence of using AC/ISM is
to enable the surgeon to determine maximal boundaries for
tumor resection while preserving neurological function. As a
result, an accurate microsurgical technique like the ones men-
tioned will fail to overpass the need for techniques in GBM
surgery such as AC/ISM.
Ultimately, we agree with Dr. Giussani and Dr. Di Cristofori
that GBM surgery would preferably be personalized, taking into
account all the patient, tumor, and molecular characteristics. The
results of our multicenter RCTwill provide vital data and results
to enable the neurosurgical community to take the next step in
creating a more standardized approach in the (surgical)
management of GBMs. Indeed, the results of this trial will give
an indication (1) if the use of AC/ISM yields superior outcomes
in GBM surgery, but more specifically (2) which GBM patients
will reap the most benefit from using AC/ISM.
Moreover and in line with their last statement, we concur
that creating an international, multicenter, prospective registry
of intraoperative techniques in GBM surgery would be highly
appreciated. We would therefore invite the letter’s authors to
participate in the ENCRAM program. The aim of ENCRAM
(European and North-American Consortium and Registry for
Awake surgery and intraoperative stimulation Mapping) is to
collect, analyze, and report clinical data of patients who have
undergone GBM surgery using AC/ISM in an international
research collaboration setting.
Research consortia and registries like ENCRAM are next
to cost-effective also highly flexible, being able to incorporate
numerous (surgical) techniques and parameters, and can be
custom-made for each participating center. In this way, com-
bining robust evidence of large-scale trials and registries has
the potential to reach (partial) consensus about the (surgical)
management of GBMs in the future.
Respectfully,
Jasper K.W. Gerritsen, MD
Arnaud J.P.E. Vincent, MD, PhD
Department of Neurosurgery, Erasmus Medical Center
Rotterdam, The Netherlands
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